{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:25:55Z","timestamp":1782602755626,"version":"3.54.5"},"reference-count":38,"publisher":"Japanese Society of Hypertension","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1291\/hypres.28.89","type":"journal-article","created":{"date-parts":[[2005,9,8]],"date-time":"2005-09-08T05:55:44Z","timestamp":1126158944000},"page":"89-95","source":"Crossref","is-referenced-by-count":63,"title":["Thrombotic Microangiopathy in Malignant Hypertension and Hemolytic Uremic Syndrome (HUS)\/Thrombotic Thrombocytopenic Purpura (TTP): Can We Differentiate One from the Other?"],"prefix":"10.1291","volume":"28","author":[{"given":"Yugo","family":"SHIBAGAKI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"FUJITA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"119","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02539-3"},{"key":"2","unstructured":"2. Khanna A, McCullough PA: Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. <i>Rev Cardiovasc Med<\/i> 2003; <b>4<\/b>: 255-259."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Moake JL: Thrombotic microangiopathies. <i>N Engl J Med<\/i> 2002; <b>347<\/b>: 589-600.","DOI":"10.1056\/NEJMra020528"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ruggenenti P, Noris M, Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. <i>Kidney Int<\/i> 2001; <b>60<\/b>: 831-846.","DOI":"10.1046\/j.1523-1755.2001.060003831.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Elliott MA, Nichols WL: Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Mayo Clin Proc <\/i>2001; <b>76<\/b>: 1154-1162.","DOI":"10.4065\/76.11.1154"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392202"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392203"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Vuylsteke P, Knockaert DC, Blockmans D, Arnout J, Vanderschueren S: Abdominal pain, hypertension, and thrombocytopenia. <i>Lancet<\/i> 2003; <b>362<\/b>: 1720.","DOI":"10.1016\/S0140-6736(03)14876-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Brain MC, Dacie JV, Hourihane DO: Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. <i>Br J Haematol<\/i> 1962; <b>8<\/b>: 358-374.","DOI":"10.1111\/j.1365-2141.1962.tb06541.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Espinosa G, Bucciarelli S, Cervera R, <i>et al<\/i>: Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. <i>Ann Rheum Dis<\/i> 2004; <b>63<\/b>: 730-736.","DOI":"10.1136\/ard.2003.007245"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shibota M, Nagaoka A, Shino A, Fujita T: Renin-angiotensin system in stroke-prone spontaneously hypertensive rats. <i>Am J Physiol<\/i> 1979; <b>236<\/b>: H409-H416.","DOI":"10.1152\/ajpheart.1979.236.3.H409"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD: Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. <i>Am J Hypertens<\/i> 1991; <b>4<\/b>: 680-687.","DOI":"10.1093\/ajh\/4.8.680"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Camargo MJ, von Lutterotti N, Campbell WG Jr, <i>et al<\/i>: Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. <i>J Hypertens<\/i> 1993; <b>11<\/b>: 31-40.","DOI":"10.1097\/00004872-199301000-00006"},{"issue":"1 Pt.2","key":"14","first-page":"451","volume":"31","year":"1998","ISSN":"https:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT Jr: Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. <i>J Am Soc Nephrol<\/i> 2003; <b>14<\/b>: 1990-1997.","DOI":"10.1097\/01.ASN.0000078960.15147.05"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Brain MC: Microangiopathic hemolytic anemia. <i>N Engl J Med<\/i> 1969; <b>281<\/b>: 833-835.","DOI":"10.1056\/NEJM196910092811507"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tsai HM: Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. <i>J Am Soc Nephrol<\/i> 2003; <b>14<\/b>: 1072-1081.","DOI":"10.1097\/01.ASN.0000060805.04118.4C"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Upshaw JD Jr: Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. <i>N Engl J Med<\/i> 1978; <b>298<\/b>: 1350-1352.","DOI":"10.1056\/NEJM197806152982407"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1038\/35097008"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.172277399"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matsumoto M, Kokame K, Soejima K, <i>et al<\/i>: Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. <i>Blood<\/i> 2004; <b>103<\/b>: 1305-1310.","DOI":"10.1182\/blood-2003-06-1796"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Remuzzi G: Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. <i>J Thromb Haemost<\/i> 2003; <b>1<\/b>: 632-634.","DOI":"10.1046\/j.1538-7836.2003.00170.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tsai HM: Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. <i>J Thromb Haemost<\/i> 2003; <b>1<\/b>: 625-631.","DOI":"10.1046\/j.1538-7836.2003.00169.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL: Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. <i>Ann Intern Med<\/i> 2000; <b>132<\/b>: 794-799.","DOI":"10.7326\/0003-4819-132-10-200005160-00005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. King AJ: Acute inflammation in the pathogenesis of hemolytic-uremic syndrome. <i>Kidney Int<\/i> 2002; <b>61<\/b>: 1553-1564.","DOI":"10.1046\/j.1523-1755.2002.00281.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Tsai HM, Chandler WL, Sarode R, <i>et al<\/i>: von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in <i>Escherichia coli<\/i> O157:H7-associated hemolytic uremic syndrome. <i>Pediatr Res<\/i> 2001; <b>49<\/b>: 653-659.","DOI":"10.1203\/00006450-200105000-00008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Pichette V, Querin S, Schurch W, Brun G, Lehner-Netsch G, Delage JM: Familial hemolytic-uremic syndrome and homozygous factor H deficiency. <i>Am J Kidney Dis<\/i> 1994; <b>24<\/b>: 936-941.","DOI":"10.1016\/S0272-6386(12)81065-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Noris M, Ruggenenti P, Perna A, <i>et al<\/i>: Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome\/Thrombotic Thrombocytopenic Purpura. <i>J Am Soc Nephrol<\/i> 1999; <b>10<\/b>: 281-293.","DOI":"10.1681\/ASN.V102281"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, <i>et al<\/i>: Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. <i>J Am Soc Nephrol<\/i> 2004; <b>15<\/b>: 787-795.","DOI":"10.1097\/01.ASN.0000115702.28859.A7"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. George JN: How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. <i>Blood<\/i> 2000; <b>96<\/b>: 1223-1229.","DOI":"10.1182\/blood.V96.4.1223.h8001223_1223_1229"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y: The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. <i>Semin Hematol<\/i> 2004; <b>41<\/b>: 68-74.","DOI":"10.1053\/j.seminhematol.2003.10.009"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. <i>Blood<\/i> 2004; <b>103<\/b>: 4043-4049.","DOI":"10.1182\/blood-2003-11-4035"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Moore JC, Hayward CP, Warkentin TE, Kelton JG: Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. <i>Blood<\/i> 2001; <b>98<\/b>: 1842-1846.","DOI":"10.1182\/blood.V98.6.1842"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01251-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Amorosi E, Ultmann J: Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. <i>Medicine<\/i> 1966; <b>45<\/b>: 139-159.","DOI":"10.1097\/00005792-196603000-00003"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DM, Benny WB: Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. <i>Br J Haematol<\/i> 1998; <b>103<\/b>: 1031-1036.","DOI":"10.1046\/j.1365-2141.1998.01080.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Gavras H, Brown WC, Brown JJ, <i>et al<\/i>: Microangipathic hemolytic anemia and the development of the malignant phase of hypertension. <i>Circ Res<\/i> 1971; <b>28 <\/b>(Suppl 2): 127-142.","DOI":"10.1161\/01.RES.28.5_Suppl_2.II-127"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Beutler JJ, Koomans HA: Malignant hypertension: still a challenge. <i>Nephrol Dial Transplant<\/i> 1997; <b>12<\/b>: 2019-2023.","DOI":"10.1093\/ndt\/12.9.2019"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T05:57:35Z","timestamp":1626501455000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nature.com\/doifinder\/10.1291\/hypres.28.89"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1291\/hypres.28.89","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}